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Abstract
Background: The interpretation of the results of active-control trials regarding the efficacy and
safety of a new drug is important for drug registration and following clinical use. It has been
suggested that non-inferiority and equivalence studies are not reported with the same quantitative
rigor as superiority studies.
Methods: Standard methodological criteria for non-inferiority and equivalence trials including
design, analysis and interpretation issues were applied to 18 recently conducted large non-
inferiority (15) and equivalence (3) randomized trials in the field of AIDS antiretroviral therapy. We
used the continuity-corrected non-inferiority chi-square to test 95% confidence interval treatment
difference against the predefined non-inferiority margin.
Results:  The pre-specified non-inferiority margin ranged from 10% to 15%. Only 4 studies
provided justification for their choice. 39% of the studies (7/18) reported only intent-to-treat (ITT)
analysis for the primary endpoint. When on-treatment (OT) and ITT statistical analyses were
provided, ITT was favoured over OT for results interpretation for all but one study, inappropriately
in this statistical context. All but two of the studies concluded there was "similar" efficacy of the
experimental group. However, 9/18 had inconclusive results for non-inferiority.
Conclusion: Conclusions about non-inferiority should be drawn on the basis of the confidence
interval analysis of an appropriate primary endpoint, using the predefined criteria for non-
inferiority, in both OT and ITT, in compliance with the non-inferiority and equivalence CONSORT
statement. We suggest that the use of the non-inferiority chi-square test may provide additional
useful information.
Background
Equivalence and non-inferiority randomized controlled
trials are the standard research methodology to demon-
strate that a new treatment is equivalent or non-inferior to
standard therapy (active-control) in term of efficacy.
While an equivalence trial would use the 2-sided 95%
confidence interval of the difference between the 2 trial
arms, the non-inferiority trial would usually use the 90%
confidence interval of the difference, if a 1-sided 5%
rather than 2.5% significance test was considered a priori
acceptable [1]. Because it is impossible to prove exact
equality, the goal in a non-inferiority trial, in situations
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where the effect compared to placebo is large, is to rule
out differences of clinical importance in the primary out-
come between the two treatments.
Issues, difficulties and controversies surrounding non-
inferiority trials have long been well recognized and
extensively reported in many medical settings, including
human immunodeficiency virus infection (HIV) [2,3].
Highly active antiretroviral therapy (HAART) delays pro-
gression of the acquired immunodeficiency syndrome
(AIDS) and increases survival among HIV infected
patients. With efficacy rates of 70% [4] and 75% [5]
respectively, the space for better antiretroviral agents effi-
cacy has become very tight. However, long term toxicities,
pill burden and genotypic resistance call for treatment
simplification and alternative new agents. As a conse-
quence, the number of non-inferiority trials has been
growing in the recent years in the AIDS therapy literature.
Some authors chose to use interchangeably the terms
"equivalence" and "non-inferiority", regardless of the
hypothesis of the study. Given that the question of inter-
est is not symmetric, we think that they are better
described as "non-inferiority" trials[6].
Because efficacy in viral suppression remains the major
outcome, new drugs should first prove non-inferiority
with respect to prolonged control of HIV replication, as
the primary endpoint. Second, the new drugs should pro-
vide other advantages. Inevitably, there may have been
some tension between marketing purposes and scientific
issues in the published reports of those trials. In this
paper, our objective was to verify the validity of recently
published non-inferiority AIDS trials regarding the pri-
mary endpoint.
Methods
Study selection and methodological standards
Our aim was to consider a cohort of equivalence or non-
inferiority trials published in the area of HIV/AIDS, after
HAART became available. We performed a MEDLINE
search using the terms equivalence OR non-inferiority
AND random* AND HIV (1) and abacavir AND random*
(2). 64 (1) and 136 (2) articles were identified. 5 (1) and
5 (2) were selected because they fulfilled the following
requirements: randomized controlled clinical trial with
48-week minimum follow-up, initially designed as a non-
inferiority or equivalence trial with a prespecified non-
inferiority margin, virological primary endpoint and pub-
lication in New England Journal Medicine, JAMA, Lancet,
AIDS, Clinical Infectious Diseases, Journal of Infectious Dis-
eases and Journal of Acquired Immune Deficiency Syndrome
between 2001 and 2006. Eight additional articles were
identified by examining cross-references or by authors'
knowledge of their existence.
We applied traditional methodological requirements for
non-inferiority and equivalence trials adapted from Kirsh-
ner[7], Jones et al. [8], McAlister and Sackett [9] and Piag-
gio et al.[1] to eighteen [10-27] active-control trials. We
also applied proposed standards in the report of non-infe-
riority and equivalence trials adapted from Le Henanff
[28].
Statistical analysis
Intent-to-treat (ITT) or on-treatment (OT) analysis 95%
confidence interval of the treatment difference were com-
puted using the normal approximation, based on availa-
ble data included in the flow chart, results section and
figures. Two selected studies (ALIZE and SEAL) predefined
a 90% confidence interval of the treatment difference, but
their conclusions were not affected by the use of the 95%
confidence interval (which was used in this paper for
homogeneity). Two other selected studies (BMS-045 and
CONTEXT) defined the primary endpoint as the log10
reduction in HIV viral load, using a time-averaged differ-
ence method. For homogeneity with other studies, we
considered the more pertinent criteria (closer to the clini-
cal practice) of the percentage of patients with undetecta-
ble viral load (< 50 copies/ml or < 400 copies/ml) at week
48 (reported as secondary endpoint).
In case of missing data, the corresponding author of the
paper was contacted. When only percentages were availa-
ble with several possibilities for the numerator due to
rounding, we choose on a worst case basis. If original data
were censored, we used the cumulative incidence of the
primary endpoint in each arm.
Significance testing in establishing non-inferiority
between the two arms of a study was computed by the use
of the continuity-corrected chi-square of Dunnett and
Gent [29] for non-inferiority in intent-to-treat or on-treat-
ment analysis, also on a worst case basis. Briefly, π1 and π2
represent the true proportions of patients with treatment
success according to the primary outcome in a random
sample of the 2 populations of patients receiving the con-
trol treatment and the new drug, respectively. In case of
non-inferiority, the expected estimates of π1 and π2 are
given by:
where x and y are the observed number of success, n1 and
n2 are the 2 sample sizes in the control and the experimen-
tal study groups, respectively and Δ the pre-specified mar-
gin for non-inferiority.
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The continuity-corrected chi-square of Dunnett and Gent
[29] (reproduced with written permission) for non-inferi-
ority is given by:
where m = x + y and   = 1 n1
If Δ is the maximal acceptable difference in success rates
between the 2 treatment arms and δ is the observed differ-
ence between the experimental and control arms, the
equivalence hypothesis can be formulated as pair of one-
sided hypothesis:
H01 : δ ≥ Δ versus Ha1 : δ < Δ with a type I error of α1      ( 1 )
and
H02 : δ ≥ - Δ versus Ha2 : δ > - Δ with a type I error of α2
 (2)
The type I error probability α for H0 rejection corresponds
to H01 ∪ H02. Therefore, the P-value for equivalence is the
lower chi-square value associated with max (α1, α2). In a
non-inferiority hypothesis, only (1) is necessary. More
details have been published elsewhere[30].
To avoid confusion between the P-values of superiority
tests and the P-values of non-inferiority tests (both are
reported in this paper), the latter have been renamed "D-
values". When the normal approximation is a valid
hypothesis, there is a general consistency between the
two-sided 95% confidence interval approach (non-inferi-
ority at α/2 < 2.5%) and the non-inferiority chi-square (D-
value < 5%), as shown in Figure 1. D-values and P-values
< 0.05 were considered statistically significant.
Results
Efficacy of the active control and similar outcome
All of the antiretroviral trials outlined in Table 1 were con-
ducted with active-controls which have previously shown
efficacy. 16 studies used a composite endpoint including
virologic failure, clinical progression to AIDS or death in
compliance with the other new AIDS clinical trials,
whereas 2 studies used log10 reduction in HIV viral load.
However, they reported virologic failure as secondary end-
points.
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Correspondence between 95% confidence interval of the difference in effect, superiority P-value and non-inferiority D-value Figure 1
Correspondence between 95% confidence interval of the difference in effect, superiority P-value and non-inferiority D-value. * 
NS indicates non-significance for superiority or non-inferiority. Case A shows significant superiority of the new drug and nec-
essarily non-inferiority Case B shows significant non-inferiority, but superiority of the new drug is uncertain (inconclusive 
result) Case C shows both, significant inferiority of the new drug (or superiority of active-control) but nonetheless significant 
non-inferiority Cases D and E failed to demonstrate non-inferiority (inconclusive result) but E demonstrated significant inferi-
ority (or superiority of active-control).
A
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Non-inferiority area
P-value D-value
<0.05 <0.05
NS* <0.05
<0.05 <0.05
NS NS
<0.05 NS
95% confidence interval of the difference in effect 
Favours the new drug  Favours the active-control drug BMC Medical Research Methodology 2006, 6:46 http://www.biomedcentral.com/1471-2288/6/46
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Rationale for the non-inferiority margin
All studies identified a pre-specified non-inferiority mar-
gin (criterion for selection). As shown in Figure 2, how-
ever, only 4/18 studies reported justification for their
choice. In the CNAAB3005 study, the choice of the non-
inferiority margin was based on discussion with clinical
investigators and with the Food and Drug Administration.
The margin of 12% was considered as the largest differ-
ence clinically acceptable. In the 903 study, the authors
considered that the margin of 10% was a more stringent
and conservative non-inferiority criterion. The authors of
the CNA30024 commented that it was the appropriate
measure for distinguishing the clinical effectiveness of 2
study treatment. Finally, the CNA30024 authors' choice
relied on HIV clinicians' judgement as well as on discus-
sion with independent reviewers. Other studies did not
comment on their choice, which ranged from 10% to 15%
(median: 12%). CONTEXT and BMS-045 considered a
non-inferiority margin of -0.5 log10 reduction in HIV viral
load, without justification. Other issues regarding design
are reported in Table 1.
Confidence interval and superiority testing
All but two trials reported results using the confidence
interval approach. In the BEST study, the authors prede-
fined their non-inferiority margin for sample size calcula-
tion, but the confidence interval was neither defined nor
reported. In the NEFA study, although the confidence
interval approach was clearly defined in the statistical
analysis section of the article, none was provided in the
results section. NEFA, BEST, 2NN, FTC-303, ESS40013
and SHAART studies reported non-significant superiority
tests for efficacy to reinforce non-inferiority. The ALIZE
and 934 studies switched from the non-inferiority to the
superiority hypothesis to declare that the experimental
treatment had superior efficacy in the ITT analysis set (for
secondary and primary endpoints, respectively), as appro-
priate.
Intent-to-treat and on-treatment analysis on the primary 
endpoint
CNAAB3005, NEFA, SOLO, BEST, EPV20001, ALIZE,
BMS-2004, SEAL and SHAART studies (Figure 2) pub-
lished both ITT and OT analysis (9/18), but only the
ALIZE, SOLO, EPV20001 BMS-2004 and SEAL studies
found concordant results regarding non-inferiority in the
two analysis. The BEST investigators provided separate
conclusions for ITT and OT, as appropriate. The ALIZE-
trial group conducted ITT, OT and a worst scenario analy-
sis. In CNAAB3005 NEFA and SHAART, the conclusion
was based on ITT analysis only. 2NN, FTC-303,
EPV20001, ESS40013, CNA30021 and 934 studies
Table 1: Characteristics of the 18 non-inferiority studies
Power (%) Double blind Experimental arm(s) (ITT sample size) Control arm (ITT sample size)
CNAAB3005 [10] NA Yes ABA (262) PI-based regimen (265)
NEFA [11] 90 No (a) NVP BID (155) EFV QD (156)
(b) ABA BID (149)
BEST [12] 90 No IDV/RITO BID (162) IDV TID (161)
2NN [13] 80 No (a) NVP QD (220) EFV (400)
(b) NVP BID (387)
(c) NVP+EFV (209)
903 [14] 80 Yes TNF (299) Stavudine (301)
SOLO [15] 85 No FPV/RITO QD (322) Nelfinavir BID (327)
FTC-303 [16] 85 No FTC QD (294) 3TC BID (146)
EPV20001 [17] 80 Yes 3TC QD (278) 3TC BID (276)
ALIZE [18] 80 No FTC-ddI-EFV QD (178) PI-based regimen BID/TID (177)
CNA30024 [19] 85 Yes ABA BID (324) AZT BID(325)
BMS-2004 [20] 90 Yes Atazanavir (405) EFV (405)
ESS40013 [21] 80 No Stop EFV (141) Continue EFV (141)
SEAL [22] 80 No 3TC+ABA QD (130) 3TC+ABA BID (130)
BMS-045 [23] NA No (a) ATA/RITO QD (120) LOPI/RITO BID (123)
(b) ATA/SAQUI (115)
CNA30021 [24] 90 Yes ABA QD (384) ABA BID (386)
CONTEXT [25] NA No (a) FPV/RITO QD (105) LOPI/RITO BID (103)
(b) FPV/RITO BID (107)
SHAART [26] 80 No ABA BID (68) NVP BID (66)
934 [27] 85 No TNF+FTC QD (255) AZT+3TC BID (259)
*one-sided 5% type I error
** one-sided 1.25% type I error
Abbreviations : NA: not available; E: equivalence; NI: non-inferiority; ABA: abacavir PI: protease inhibitor ; NVP: nevirapine ; EFV: efavirenz ; IDV: 
indinavir ; RITO: ritonavir ; TNF : tenofovir ; FPV: fosamprenavir; FTC : emtricitabine; 3TC: lamivudine ; ddI: didanosine ; AZT : zidovudine ; QD: 
once-a-day ; BID: twice-a-day ; TID three times-a-dayBMC Medical Research Methodology 2006, 6:46 http://www.biomedcentral.com/1471-2288/6/46
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described sufficient details to permit alternative analyses,
such as OT. We have failed to compute OT analysis from
the 903 and CNA30024 studies. Because of the nature of
their primary outcome, CONTEXT and BMS-045 studies
were not able to provide ITT and OT analysis. Both analy-
sis were provided as secondary endpoints.
Interpretation and conclusion (non-inferiority margin 
versus observed upper bound of the 95% confidence 
interval of the difference)
CNAAB3005 (12% versus 14.3), NEFA (13.5% versus
15.8), 2NN (10% versus 14.0%; 10% versus 14.6%), 903
(10% versus 10.3%) and SHAART (15% versus 17.4%)
concluded non-inferiority inappropriately on the basis of
their pre-specified margin. In accordance, their non-infe-
riority D-values were above 5%, as shown in Table 2.
BMS-2004 concluded that the two drugs were as effica-
cious (suggesting equivalence), while the ITT lower bound
of the 95% confidence interval (-11.7%) exceeded 10% in
favour of the experimental drug. The main BMS-2004
hypothesis (non-inferiority of the experimental drug at
10%) was demonstrated with a D-value = 0.043 (OT anal-
ysis). In our analysis of the ESS40013 study (OT), thenon-
inferiority margin exceeded the pre-specified non-inferi-
ority margin. Finally, CONTEXT and BMS-045 studies
provided a conclusion in accordance with their non-infe-
riority margin (data not shown).
BEST, SOLO, FTC-303, EPV20001, ALIZE, CNA30024,
SEAL, CNA30021 and 934 conclusions' were appropriate,
on the basis of available data.
Discussion
Trials that assess non-inferiority require rigorous methods
for their design, analysis and interpretation. Although the
design and the sample size were appropriate for AIDS
non-inferiority and equivalence trials, there is room for
substantial improvement regarding statistical analysis and
interpretation of the results.
Patients with HIV infection would be harmed by deferral
of therapy. Consequently, the use of placebo would be
unethical [2]. Even if placebo-controlled of HAART ther-
apy are not available, a conclusion about efficacy can be
reached because the great majority of patients (about
70%) will not be controlled without treatment [4,5].
Because significant inferiority to active-control would be a
major problem for patients, the non-inferiority margin for
a new drug should be smaller than the difference between
active-control and placebo. Because this effect size is so
large, only the clinically chosen margin is really an issue,
but is also highly subjective. As a result, this margin varied
from the conventional 10% up to 15%. Even the same
study group chose different margins in studies 903 (10%)
and 934 (13%). A small decrease in margin provides
greater assurance of satisfactory effect, but the cost of the
study will increase because more patients are required. In
the 903-study, the authors could not demonstrate non-
inferiority at 10% but they point out in their discussion
that this margin was more stringent than the 12% chosen
in CNAAB4005. However, if the authors had chosen the
less powerful 12% as the maximal limit for non-inferior-
ity, the 95% confidence interval would have been wider,
possibly beyond the 12% limit. Consequently, data-
driven discussion about the non-inferiority margin after
completion of the study is pointless.
Blinding has been described as less efficient in non-inferi-
ority than superiority trials, in particular if the primary
endpoint is subjective[31]. For example, a blinded inves-
tigator could bias the results toward a preconceived belief
Quality report assessment of non-inferiority trials adapted  from Le Henanff et al. [28] Figure 2
Quality report assessment of non-inferiority trials adapted 
from Le Henanff et al. [28]. 1. Report the margin and the jus-
tification for its choice 2. Appropriate sample size calculation 
3. Report both on-treatment and intent-to-treat analysis for 
the primary endpoint 4. Report 1-sided or 2-sided confi-
dence intervals of treatment difference 5. Conclusion 5.1 
Conclude non-inferiority or equivalence only if both ITT and 
OT analyses permit that or provide separate conclusions. 
5.2. Restate the prespecified margin in the abstract 5.3 Make 
interpretation according to the margin of equivalence or 
non-inferiority regarding of the primary endpoint 5.4 Con-
clude with standard and appropriate vocabulary in accord-
ance with the aim and the results of the trial (ie, "non-inferior 
to" or "equivalent to").
1 2 3 4 5.1 5.2 5.3 5.4  Journal 
CNAAB3005  JAMA
NEFA         NEJM 
BEST AIDS 
2NN  Lancet
903  JAMA
SOLO  AIDS 
FTC-303  AIDS 
EPV20001  CID
ALIZE JID
CNA30024  CID
BMS-2004  JAIDS
ESS40013  JAIDS
SEAL JAIDS
BMS-045  AIDS 
CNA30021  CID
CONTEXT  Unpublished 
SHAART  JAIDS
934  NEJM 
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Table 2: Results of the 18 non-inferiority studies
Δ Maximum difference % 
(hypothesis)
δ (%)* UBCI§ of δ (%) Non-inferiority D-value 
(type of analysis)
Superiority P-value (ITT) Abstract authors' conclusion as compared with 
active-control for primary endpoint
CNAAB3005 12 (E) 7.3 14.3 0.17 (OT) 0.90 Was equivalent to
NEFA 13.5 (NI)
(a) 3.9 9.8 < 0.001 (ITT) 0.20 No conclusion
(b) 8.5 15.8 0.14 (OT) 0.035 A trend toward higher rate of [failure]
BEST 15 (NI) 15.7 (ITT) 25.9 (ITT) 1.0 (ITT) 0.003 Superiority of control in ITT
0.7 (OT) 7.2 (OT) < 0.001 (OT) 1.0 (OT) Non-inferiority in OT
2NN 10 (E)
(a) 5.9 14.0 0.36 (ITT) 0.15 Showed similar efficacy
(b) 7.7 14.6 0.56 (OT) 0.091** Showed similar efficacy
(c) 15.4 23.6 0.24 (ITT) 0.0003 Did not show efficacy
903 10 (NI) 4.1 10.3 0.07 (ITT) 0.19 Highly effective and comparable***
SOLO 12 (NI) -1.0 6.1 < 0.001 (ITT) 0.78 Provided durable [efficacy]
FTC-303 15 (NI) 5.0 12.9 < 0.01 (ITT) 0.234 Was equivalent to
EPV20001 12 (E) -0.1 3.6 < 0.001 (OT) 0.81 Regimens were equivalent
ALIZE 15 (NI*) -2.9 3.6 < 0.001 (ITT) 0.39 Associated with sustained [efficacy]
CNA30024 12 (NI) -0.8 -6.3 < 0.001 (ITT) 0.82 Not inferior to
BMS-2004 10 (NI) 3.9 9.7 0.043 (OT) 0.16 As efficacious as
ESS40013 12 (NI) 6.1 13.5 0.09 (OT) 0.77 Maintained [efficacy]
SEAL 12 (NI*) -1.5 4.3 < 0.001 (ITT) 0.61 Not inferior to
BMS-045 NA (NI)
(a) 8.0*** 20.4*** NA (ITT) 0.21 As effective as
(b) 19.5*** 32.2*** NA (ITT) 0.003 Efficacy was lower than
CNA30021 12 (NI) 2.2 6.6 < 0.001 (OT) 0.61 Not inferior to
CONTEXT NA (NI)
(a) 14.0*** 28.0*** NA (OT) 0.07 Not shown to be as effective as
(b) 10.0*** 23.0*** NA (ITT) 0.30 Not shown to be as effective as
SHAART 15 (NI) 2.1 17.4 0.13 (ITT) 0.784 Not inferior to
934 13 (NI) -3.5 0.5 < 0.001 (OT) < 0.005 Fulfilled criteria for non-inferiority and proved superior
§ Bold UBCI exceeded the pre-specified non-inferiority margin
*A positive δ corresponds to a higher efficacy of the active-control group, as compared with the experimental group. We choose the OT or ITT in a worst case basis, unless the authors reached separate 
conclusions for OT and ITT. The numbers may differ from original reports because original reports were stratum-adjusted or used 90% confidence interval.
** If patients who never started treatment were excluded, P = 0.03
***Based on secondary endpoints
Abbreviations: δ : Observed difference between the % of success observed in the control arm minus the % of success observed in the experimental arm ; UBCI : upper bound of the 95% confidence interval; 
E: equivalence; NI: non-inferiorityBMC Medical Research Methodology 2006, 6:46 http://www.biomedcentral.com/1471-2288/6/46
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in equivalence by assigning similar ratings to the treat-
ment responses of all patients, giving a "bias toward the
null". Even when the primary outcome is objective (viral
failure, clinical progression or death), however, we believe
that blinding is important to protect against bias.
Unblinded investigators may provide other effective ther-
apies to patients in the arm that they believe superior or
equivalent, such as more regular appointment or adher-
ence support. In addition, patient or physicians may over-
interpret subjective endpoints such as side-effects in open-
label studies. Finally the absence of blinding can distort
the comparability of the groups regarding study with-
drawal or patients' adherence, since patients participating
in a non-inferiority trial may prefer to receive the simpler
therapy. Among the studies observed, significantly more
patients discontinued the ALIZE study medication in the
control arm for personal reasons, as compared with the
simpler, once-a-day experimental group (11% versus 2%,
P < 0.0004). This may influence outcome, particularly in
an ITT analysis, where withdrawals are considered as fail-
ure. Another example comes from the results of the 934
study, where adherence to treatment differed significantly
between groups. The conclusion about superior efficacy of
the experimental arm in the 934-study may be in part the
consequence of greater exposure to the experimental drug.
On the other hand, blinding can stand in the way of an
optimal drug dispensation in non-inferiority and equiva-
lence trials, in particular if the aim is to simplify antiretro-
viral therapy. For example, if the purpose is to offer
simpler dosage or fewer pills as compared to standard
therapy, blinding may require similar regimens in both
arms so that any advantages of simplification would be
eliminated.
Exclusion of patients after they have been randomized
sacrificed the validity of "on-treatment" analysis because
it may cause major bias regarding group comparability.
For this reason, intention-to-treat analyses has been recog-
nized as the most appropriate and conservative strategy to
analyse data of double-blinded trials. However, in case of
non-inferiority and equivalence trials, it is well known
that this method lacks of robustness since not conserva-
tive. For this reason, the study interpretation should also
be complemented by "on-treatment analysis"[1,8,9]. If
there are discrepancies in the results regarding equiva-
lence or non-inferiority, this should be reported and
acknowledged. The CNAAB3005 illustrated how apparent
equivalence can be the consequence of a dilutional effect
of comparing 2 treatments in the ITT (527 patients) when
only 54% of the patients where on-treatment. The same
could apply to the ESS40013 study. The use of an "over-
all" log-rank testing superiority within the 3 arms in the
NEFA study may also have blurred the lower efficacy of
one study arm, as demonstrated by the "head-to-head"
comparison between abacavir and efavirenz.
Like in superiority trials, the choice of the primary out-
come is also critical in non-inferiority trials. The BMS-045
illustrated how statistical non-inferiority for viral log dif-
ference can be compatible with up to 20.4% of additional
virologic failure in the experimental arm, a percentage
much larger than non-inferiority margins usually selected
for this outcome in this setting.
Finally, the majority of the studies concluded that the
effect of at least one experimental arm, based on their pre-
specified margin, was similar to the control. However,
only half of these studies actually demonstrated non-infe-
riority. Prespecifying the non-inferiority or equivalence
margin is necessary but not sufficient to guaranty method-
ologic quality and appropriate conclusion. We confirmed
that AIDS trialists had low adherence to non-inferiority
and equivalence methodological standards, as it is the
case in other fields[28]. An antiretroviral drug may not
prove non-inferiority in term of efficacy but nonetheless
be a good alternative because the observed difference is
small and the new drug demonstrates better tolerance.
This interpretation should, however, be left to the reader.
To allow a risk-benefit assessment to be made, the report
has a particular obligation to be as clear as possible, using
standard statistical vocabulary for non-inferiority and
equivalence trials, in compliance with the CONSORT
statement.
Conclusion
Conclusions about non-inferiority should be drawn on
the basis of an appropriate confidence interval using a
predefined criterion for non-inferiority, shown in both
OT and ITT in compliance with the non-inferiority and
equivalence extension of the CONSORT statement[1]. We
describe how failure to do so will lead to erroneous con-
clusions. A claim of non-inferiority with a non-inferiority
chi-square D-value above 5% is as incorrect as a claim of
superiority with traditional null hypothesis testing P-
value above 5%. Although the 95% confidence approach
is sufficient to reject the null hypothesis, the non-inferior-
ity chi-square provides additional information about the
actual degree of significance. Of note, the revised CON-
SORT statement for superiority trials, item 12a[32] recom-
mends the report of the actual P-values for statistical
significance rather than the imprecise threshold "P <
0.05". The additional use of the continuity-corrected non-
inferiority chi-square may contribute to avoid misleading
interpretation by non-statisticians, for whom significance
testing may have a higher impact than confidence inter-
vals. The clinical relevance of the primary outcome on
which non-inferiority rely should also be assessed.
Reviewers and Editors need to reinforce their standards for
acceptance of non-inferiority and equivalence rand-
omized controlled trial. Finally, the importance of critical
appraisal has implications for both curricular planning inBMC Medical Research Methodology 2006, 6:46 http://www.biomedcentral.com/1471-2288/6/46
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schools and colleges of medicine, as well as for continuing
education programs.
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